Core Viewpoint - The company is focusing on increasing its R&D expense ratio to 18.2% in 2024, with significant investments in high-end instruments and new technologies such as terahertz and gene sequencing, while facing pricing competition from major players like Thermo Fisher [1] Group 1: R&D and Investment - The company plans to allocate 18.2% of its budget to R&D in 2024, emphasizing high-end instruments and new technologies [1] - The company is under pressure from competitors like Thermo Fisher, which are reducing prices [1] Group 2: Domestic Production and Product Impact - The current domestic production rate for core components, such as ion sources and vacuum pumps, has improved, but specific percentages depend on product category and procurement standards [1] - The impact of new products from Pukang Medical and Juzhi Biotechnology on the company's overall business is currently minimal [1]

Group 1 - The core viewpoint of the article highlights that Kunming University of Science and Technology has announced a government procurement intention for laboratory equipment, with a total budget of 125 million yuan [1][2]. - The procurement involves 96 sets of teaching and research instruments, including a micro-manipulation workstation, mass cytometry flow cytometer, and large-scale fully electric cryostat [2][4]. - The expected procurement date is set for May 2025, aimed at enhancing the university's teaching and research capabilities [2][4]. Group 2 - The procurement is part of a broader initiative to align the university's strengths with the industrial development of Yunnan Province, focusing on new materials, biomedicine, health, modern agriculture, and renewable energy [4]. - The intention is to ensure that faculty and students have access to the latest technologies and to promote the integration of industry and academia [4].